Replies to post #94518 on Biotech Values

[DewDiligence]

I have friends who are now on Atripla. Is there any compelling reason for them to switch to TMC278 + Truvada, should that regimen be approved?

TMC278 presumably has a lower rate of SAE’s than Sustiva, the corresponding non-nuke component of Atripla. I use the word presumably because JNJ has not yet disclosed the data from the TMC278 phase-3 trials.